According to the American Cancer Society, breast cancer is the second most common newly diagnosed cancer and second leading cause of cancer death among women in the U.S. Early detection and treatment of a tumor can result in a greater chance of surviving breast cancer, however, the procedures are often painful and time consuming. Knowing this, Sanarus Technologies set out with one mission: to improve the standard of care for breast tumors.
The Sanarus team is committed to women’s health and dedicated to providing an alternative choice to the traditional lumpectomy. They deliver a minimally invasive solution that is completed in an outpatient environment resulting in a procedure that is more effective than surgery, performed at a lower cost, painless and requires zero downtime. In short, the company has changed the way women view the treatment of breast tumors.
Sanarus serves women afflicted with breast tumors with their trailblazing technology known as the Visica 2TM Treatment System. Invented and patented by Sanarus, this low-pressure liquid nitrogen cryotherapy system was the first of its kind available to those with breast tumors. Embraced by doctors everywhere for being both safe and effective, it has been used to treat over 4,000 successful cases to date.
“Being a woman, I understand that this is a very difficult time for patients and their family,” said Chairman, BJ Hardman. “That’s why we are committed to providing the information and education needed to make an informed decision. Our goal is to make the treatment of breast tumors more efficient while providing the highest quality of care.”
The company prides themselves in pioneering minimally invasive breast care solutions for both benign tumors and breast cancer. They are a woman-owned business, headquartered in Pleasanton, CA, and all of their products are manufactured in the U.S. Though they have had much success over the years, Sanarus is firm on the fact that they are not done paving the way for an even brighter future. They continue to push the envelope with new technologies and clinical trials, with the continued goal of providing the best, most effective care possible.